Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

See Which of These Three Tuesday Losers Hedge Funds Say You Should Buy on the Dip

Page 1 of 2

It seems that the U.S. equity markets are bouncing back from Monday’s substantial pullback, but there are some stocks that have been beaten down quite seriously by the market. The S&P 500 Index has advanced by more than 0.50% so far today, narrowing down yesterday’s loss of 2.57%. Esperion Therapeutics Inc. (NASDAQ:ESPR), Team Inc. (NYSE:TISI), and Galapagos NV (ADR) (NASDAQ:GLPG) are the major losers of today’s trading session, and the following article will discuss what stands behind their disappointing performance and will assess the hedge fund sentiment towards them.

But first, you should get familiar with what Insider Monkey can offer besides the high-quality evidence-based articles. At Insider Monkey, we track hedge funds’ moves in order to identify actionable patterns and profit from them. Our research has shown that hedge funds’ large-cap stock picks historically lagged the S&P 500 Total Return Index by an average of seven basis points per month between 1999 and 2012. On the other hand, the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Index by an average of 95 basis points per month (read more details here). Since the official launch of our small-cap strategy in August 2012, it has performed just as predicted, returning over 118% and beating the market by more than 60 percentage points. We believe the data is clear: investors will be better off by focusing on small-cap stocks utilizing hedge fund expertise (while avoiding their high fees at the same time) rather than large-cap stocks.

We will begin our discussion by analyzing the reasons that have caused the major sell-off of Esperion Therapeutics Inc. (NASDAQ:ESPR)’s shares during today’s trading session. The pharmaceutical company, that engages in the development and commercialization of a first-in-class, oral therapy for low-density lipoprotein cholesterol (LDL-C) lowering, has released an update on its planned Phase 3 trial. Esperion Therapeutics outlined that it intends to carry out several Phase 3 clinical trials that will independently investigate two groups of patients. However, it appears that that the FDA has “encouraged’ the company to start on a cardiovascular outcomes study that needs to be finalized by the time of the New Drug Application submission and review, which might serve as the primary reason why the market reacted so negatively to the update. Esperion’s stock has plummeted by more than 35% so far today, widening the year-to-date loss to 44%. In the meantime, there were 28 hedge funds tracked by us with long positions in Esperion at the end of the second quarter, compared to 24 reported in the prior quarter. Nevertheless, the value of their holdings decreased during the three-month period to $589.13 million from $590.73 million. It is also worth noting that these 28 investors amassed 32.0% of the company’s outstanding shares on June 30. Dennis Purcell’s Aisling Capital is the top equity holder of Esperion Therapeutics Inc. (NASDAQ:ESPR) within our database, holding 1.64 million shares.

Follow Esperion Therapeutics Inc. (NASDAQ:ESPR)
Trade (NASDAQ:ESPR) Now!
Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!